FMA
HRTX icon

FNY Managed Accounts’s Heron Therapeutics HRTX Stock Holding History

FNY Managed Accounts’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,700
Closed -$17.1K – 385
2014
Q4 		$17.1K Buy
+1,700
New +$13.9K 0.02% 164

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FNY Managed Accounts's HRTX Position: Q1 2015 in Review

FNY Managed Accounts sold out of Heron Therapeutics (HRTX) in Q1 2015, closing a stake of 1,700 shares — an estimated $17.1K sold.

FNY Managed Accounts first reported a position in HRTX in Q4 2014 and held it in 1 quarter. The position peaked at $17.1K in Q4 2014. 69 funds tracked by Wall St. Rank hold HRTX as of Q1 2015.

  • FNY Managed Accounts reported no remaining Heron Therapeutics position as of Q1 2015 after selling out during the quarter.
  • FNY Managed Accounts sold 1,700 Heron Therapeutics shares in Q1 2015, an estimated $17.1K.
  • FNY Managed Accounts first reported a position in Heron Therapeutics in Q4 2014 and held it in 1 quarter.
  • FNY Managed Accounts's Heron Therapeutics position peaked at $17.1K in Q4 2014.
  • 69 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2015.

Based on FNY Managed Accounts's 13F filing for Q1 2015, filed 6 May 2015.